Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP1244202.RAUJbaEZpae4ZfaKXs_k39C6XVr1PmRPGc4naT4ZmSJMs130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244202.RAUJbaEZpae4ZfaKXs_k39C6XVr1PmRPGc4naT4ZmSJMs130_provenance.
• NP1244208.RAXIg6iDQoLNaYsciGagRTQ3dJ4e19sgrroK2DTUA06Cg130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244208.RAXIg6iDQoLNaYsciGagRTQ3dJ4e19sgrroK2DTUA06Cg130_provenance.
• NP1244214.RAat1ej27iBU4MslxJTEAkt5Xzu03haQe-8vEMPrRMw7E130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244214.RAat1ej27iBU4MslxJTEAkt5Xzu03haQe-8vEMPrRMw7E130_provenance.
• NP1244216.RAb2_yQVQ1tH2dihIYwBs3KO-pWLIF7hT1QJ5yAxKYvpg130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244216.RAb2_yQVQ1tH2dihIYwBs3KO-pWLIF7hT1QJ5yAxKYvpg130_provenance.
• NP1244211.RADkVOffWQybUjoQvj2EQmdsxbvcv0TdLpWAN0RRm_yKU130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244211.RADkVOffWQybUjoQvj2EQmdsxbvcv0TdLpWAN0RRm_yKU130_provenance.
• NP1244204.RAoOr0UNvv0tW0cWN6zhCUpJ2BBan5H0jc9pxDdSAEyCQ130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244204.RAoOr0UNvv0tW0cWN6zhCUpJ2BBan5H0jc9pxDdSAEyCQ130_provenance.
• NP1244205.RAtuaSLgrsr5nGfcI4iCNGgZkYvXA-HBKuyb2oFO4fG0Q130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244205.RAtuaSLgrsr5nGfcI4iCNGgZkYvXA-HBKuyb2oFO4fG0Q130_provenance.
• NP1244209.RAoTdY1At5UGwdD7az_ZoHALNwCEUlwfDHjqScIC4zvvk130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244209.RAoTdY1At5UGwdD7az_ZoHALNwCEUlwfDHjqScIC4zvvk130_provenance.
• NP1244210.RAmb4XMtqfjtUxofaOvjrjI1Qzd0dMaTdQFp0xNj9Vvz0130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244210.RAmb4XMtqfjtUxofaOvjrjI1Qzd0dMaTdQFp0xNj9Vvz0130_provenance.
• NP1244212.RAobixfJI0--9c5RY1kU4uoSVhZ4H_otYHiW1Q15iGIM0130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244212.RAobixfJI0--9c5RY1kU4uoSVhZ4H_otYHiW1Q15iGIM0130_provenance.
• NP1244215.RAscDnc7kc8Hn6Us-BdZbdYHYVObPgcgL-pm_U8RNBCc8130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244215.RAscDnc7kc8Hn6Us-BdZbdYHYVObPgcgL-pm_U8RNBCc8130_provenance.
• NP1244218.RAoZdCCBLwOGbmIUd3D-7GAfWjfY6Qzd4bPs0HjwpXu6g130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244218.RAoZdCCBLwOGbmIUd3D-7GAfWjfY6Qzd4bPs0HjwpXu6g130_provenance.
• NP1244213.RAJ-w3jDC3rVJ99TfU-18ggvNRuAw4OPBwKGVCC_Iwg9o130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244213.RAJ-w3jDC3rVJ99TfU-18ggvNRuAw4OPBwKGVCC_Iwg9o130_provenance.
• NP1244201.RA_OFopysnNcg_Ctxk3npDHCYe1KevJP5_2UMUayWRyLI130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244201.RA_OFopysnNcg_Ctxk3npDHCYe1KevJP5_2UMUayWRyLI130_provenance.
• NP1244203.RAzRDT4zIv9HlOh_Qd8LryDqmES3lKbxYrR-uubX5PqHU130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244203.RAzRDT4zIv9HlOh_Qd8LryDqmES3lKbxYrR-uubX5PqHU130_provenance.
• NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.
• NP1244207.RAx62m3V0d-QkW7N9-wWvQaB9-ZS5_QIFcBcKIkhOAAvw130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244207.RAx62m3V0d-QkW7N9-wWvQaB9-ZS5_QIFcBcKIkhOAAvw130_provenance.
• NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.